Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 225,289,906 papers from all fields of science
Search
Sign In
Create Free Account
YM 216391
Known as:
YM-216391
, YM216391
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
2 relations
Broader (2)
Cyclic Peptides
Oxazoles
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2012
2012
Analysis of YM-216391 biosynthetic gene cluster and improvement of the cyclopeptide production in a heterologous host.
Xiao-hong Jian
,
Hai-Xue Pan
,
+6 authors
G. Tang
ACS Chemical Biology
2012
Corpus ID: 10689396
YM-216391, an antitumor natural product, represents a new class of cyclic peptides containing a polyoxazole-thiazole moiety…
Expand
2005
2005
YM-216391, a Novel Cytotoxic Cyclic Peptide from Streptomyces nobilis
K. Sohda
,
K. Nagai
,
T. Yamori
,
Ken-ichi Suzuki
,
A. Tanaka
Journal of antibiotics (Tokyo. )
2005
Corpus ID: 21028598
AbstractYM-216391, a novel cyclic peptide, was isolated from the cultured mycelium of Streptomyces nobilis JCM 4274. It was…
Expand
2005
2005
YM-216391, a Novel Cytotoxic Cyclic Peptide from Streptomyces nobilis
K. Sohda
,
M. Hiramoto
,
K. Suzumura
,
Y. Takebayashi
,
Ken-ichi Suzuki
,
A. Tanaka
Journal of antibiotics (Tokyo. )
2005
Corpus ID: 19445218
AbstractYM-216391, a novel cytotoxic cyclic peptide, has been isolated from the cultured mycelium of Streptomyces nobilis JCM…
Expand
2005
2005
Synthesis and establishment of stereochemistry of the unusual polyoxazole-thiazole based cyclopeptide YM-216391 isolated from Streptomyces nobilis.
Jon M. S. Deeley
,
G. Pattenden
Chemical Communications
2005
Corpus ID: 29705722
A concise total synthesis of the unusual oxazole-based cyclopeptide structure YM-216391, which also establishes the…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE